(Q38008152)

26 August 2017

title

Anticoagulant therapy for patients with ischaemic stroke (English)

1 reference

26 August 2017

1 reference

1 reference

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 May 2012

1 reference

26 August 2017

published in

Nature Reviews Neurology

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

319-328

1 reference

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Underuse of oral anticoagulants in atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Dabigatran etexilate: a new oral thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

The role of tissue factor and factor VIIa in hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban‐treated patients: results of an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Laboratory assessment of new anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Medication adherence: its importance in cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K an

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Bleeding risk assessment and management in atrial fibrillation patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

What do the results of the PRoFESS trial teach us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Worldwide management of oral anticoagulant therapy: the ISAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Anticoagulants for acute ischaemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Newly identified events in the RE-LY trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.77

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22565207

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22565207

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22565207

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2012.77

1 reference

Dimensions Publication ID

26 August 2017

1039462305

0 references

1 reference